Inari Medical (NARI)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Inari Medical (NARI)
Inari Medical Inc is a medical device company focused on developing products to treat patients suffering from Chronic Venous Disease. Its product portfolio includes; ClotTriever, for the removal of the clot from peripheral blood vessels and treats patients suffering from deep vein thrombosis. The FlowTriever System product is used for the treatment of pulmonary embolism, InThrill system to treat small vessel thrombosis, LimFlow system and others. Geographically, the company generates majority of its revenue from United States and rest from International markets.
Key Insights
Critical company metrics and information
Share Price
$54.27Market Cap
$3.18 BillionTotal Outstanding Shares
58.54 Million SharesTotal Employees
1,300Dividend
No dividendIPO Date
May 22, 2020SIC Description
Surgical & Medical Instruments & ApparatusHomepage
https://www.inarimedical.com
Historical Stock Splits
Execution Date | Split Amount |
---|---|
No Historical Stock Splits |
Cash Flow Statement
July 1, 2023 to June 30, 2024
Metric | Value |
---|---|
Net Cash Flow From Financing Activities | $-681,000.00 |
Exchange Gains/Losses | $125,000.00 |
Net Cash Flow | $12.36 Million |
Net Cash Flow From Financing Activities, Continuing | $-681,000.00 |
Net Cash Flow From Investing Activities | $-14.49 Million |
Net Cash Flow, Continuing | $12.23 Million |
Net Cash Flow From Operating Activities | $27.41 Million |
Net Cash Flow From Operating Activities, Continuing | $27.41 Million |
Net Cash Flow From Investing Activities, Continuing | $-14.49 Million |
Income Statement
July 1, 2023 to June 30, 2024
Metric | Value |
---|---|
Basic Earnings Per Share | $-0.98 |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0.00 |
Benefits Costs and Expenses | $582.57 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $0.00 |
Costs And Expenses | $582.57 Million |
Net Income/Loss Available To Common Stockholders, Basic | $-57.05 Million |
Income Tax Expense/Benefit | $21.96 Million |
Net Income/Loss | $-57.05 Million |
Operating Income/Loss | $-46.80 Million |
Gross Profit | $477.11 Million |
Diluted Earnings Per Share | $-0.99 |
Basic Average Shares | $173.76 Million |
Preferred Stock Dividends And Other Adjustments | $0.00 |
Selling, General, and Administrative Expenses | $406.99 Million |
Operating Expenses | $523.91 Million |
Net Income/Loss Attributable To Parent | $-57.05 Million |
Income/Loss From Continuing Operations Before Tax | $-35.09 Million |
Revenues | $547.47 Million |
Research and Development | $96.17 Million |
Income/Loss From Continuing Operations After Tax | $-57.05 Million |
Diluted Average Shares | $172.94 Million |
Cost Of Revenue | $70.37 Million |
Balance Sheet
July 1, 2023 to June 30, 2024
Metric | Value |
---|---|
Equity | $423.81 Million |
Noncurrent Liabilities | $110.86 Million |
Other Current Assets | $199.99 Million |
Accounts Payable | $16.38 Million |
Equity Attributable To Parent | $423.81 Million |
Liabilities And Equity | $672.93 Million |
Intangible Assets | $143.11 Million |
Other Current Liabilities | $67.52 Million |
Wages | $54.36 Million |
Assets | $672.93 Million |
Liabilities | $249.12 Million |
Current Liabilities | $138.26 Million |
Current Assets | $249.35 Million |
Other Non-current Assets | $257.47 Million |
Equity Attributable To Noncontrolling Interest | $0.00 |
Inventory | $49.36 Million |
Noncurrent Assets | $423.58 Million |
Fixed Assets | $23.00 Million |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
â“’ 2024 Financhle. All Rights Reserved.